Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020002 · ClinicalTrials.gov registry record
Extracellular RNA Biomarkers of Myotonic Dystrophy
A clinical trial of Myotonic Dystrophy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 215
- Enrollment target
- 3
- Study locations
NCT05020002: Recruiting study of Myotonic Dystrophy, sponsored by Massachusetts General Hospital.
NCT05020002 is a study of Myotonic Dystrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 215 participants, below the 832-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05020002, a study of Myotonic Dystrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 215 participants
- Enrollment target
- 3
- Study locations
Study Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.
Primary Outcome
The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity.
Conditions Studied
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2027-12 |
What NCT05020002 shows while recruiting
NCT05020002 is an observational study that tracks outcomes without assigning an intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, below the 832-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Myotonic Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05020002 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT05020002 about?
NCT05020002 is a clinical study titled "Extracellular RNA Biomarkers of Myotonic Dystrophy". Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is t...
What is the current status of trial NCT05020002?
This trial is currently recruiting. The enrollment target is 215 participants. The study started on 2020-12-08. Estimated completion is 2027-12.
What conditions does trial NCT05020002 study?
This clinical trial studies the following conditions: Myotonic Dystrophy.
Who is sponsoring clinical trial NCT05020002?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020002 being conducted?
This trial has 3 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05020002's enrollment target sits among peer trials
215 4th of 9 higher than 6 of 9 other Myotonic Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myotonic Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Myotonic Dystrophy Family Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI